IRONWOOD PHARMACEUTICALS, INC. Treasury Stock Acquired, Average Cost Per Share
IRONWOOD PHARMACEUTICALS, INC. (IRWD) reported Treasury Stock Acquired, Average Cost Per Share of $11.47 per share for the 22-month period ending 2023-09-30, per its 10-Q filed 2023-11-09.
Discontinued › Income Statement › Earnings Per Share
us-gaap:TreasuryStockAcquiredAverageCostPerShare · last filed 2023-11-09
- 2023-09-30: Treasury Stock Acquired, Average Cost Per Share 22 month $11.47.
| Period end | Treasury Stock Acquired, Average Cost Per Share 22 month |
|---|---|
| 2023-09-30 | $11.47 10-Q · filed 2023-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |